Clinical Trials
6 trialsNCT01979523 2026-04-13
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01989598 2022-03-02
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01941927 2020-02-12
Trametinib With GSK2141795 in BRAF Wild-type Melanoma
University of California, San Francisco
Phase 2 Completed
NCT01964924 2019-09-20
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01958112 2019-05-31
GSK1120212+GSK2141795 for Cervical Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01907815 2018-04-06
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated